BKHA Black Hawk Acquisition Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2000775 · Fiscal year ends 11/30
Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-08-31 | 2026Q22026-05-31 | 2026Q12026-02-28 | 2025Q4*2025-11-30 | 2025Q32025-08-31 | 2025Q22025-05-31 | 2025Q12025-02-28 | 2024Q4*2024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $108,210 | $79,215 | $24,189 | $187,878 | $311,265 | $217,598 | $78,769 | $71,268 |
| Operating income | -$138,210 | -$109,215 | -$54,189 | -$217,878 | -$341,265 | -$247,598 | -$108,769 | -$101,268 |
| Interest expense | $33,226 | $24,381 | $19,449 | — | — | — | — | — |
| Net income | $1.07M | $88,929 | $139,805 | -$3,765 | $154,401 | $520,542 | $658,379 | $751,701 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Banking | ||||||||
| Net interest income | $230,184 | $222,525 | $213,442 | $230,578 | $494,519 | $767,623 | $765,911 | $850,603 |
| Deposits | $690,000 | $690,000 | $690,000 | $690,000 | $690,000 | $690,000 | $690,000 | $690,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $0 | $0 | $0 | $0 | $15,000 | $72,914 | $101,528 | $264,842 |
| Current assets | $41,367 | $63,130 | $181,352 | $50,790 | $44,530 | $139,523 | $205,262 | $314,071 |
| Intangibles | $5.00M | $5.00M | $5.00M | $5.00M | $5.00M | — | — | — |
| Total assets | $26.03M | $25.38M | $24.82M | $23.88M | $23.34M | $73.50M | $72.80M | $72.14M |
| Current liabilities | $2.34M | $2.75M | $2.29M | $1.48M | $946,168 | $251,043 | $69,701 | $70,978 |
| Total liabilities | $4.75M | $5.17M | $4.70M | $3.90M | $3.36M | $2.67M | $2.48M | $2.49M |
| Shareholders' equity | -$4.71M | -$5.10M | -$4.52M | -$3.85M | -$3.32M | -$2.53M | -$2.28M | -$2.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$113,451 | -$236,637 | -$109,502 | -$100,479 | -$107,914 | -$278,614 | -$163,314 | -$59,004 |
| Investing cash flow | -$450,000 | -$450,000 | -$600,000 | -$300,000 | — | — | — | $0 |
| Financing cash flow | $563,920 | $519,813 | $848,388 | $425,000 | -$50.51M | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.